RetroSPECT: Gallium-۶۷ as a Long-Lived Imaging Agent for Theranostics
سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 269
فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_JNMB-9-1_001
تاریخ نمایه سازی: 14 اردیبهشت 1400
چکیده مقاله:
A limitation to the wider introduction of personalised dosimetry in theranostics is the relative paucity of imaging radionuclides with suitable physical and chemical properties to be paired with a long-lived therapeutic partner. As most of the beta-emitting therapeutic radionuclides emit gamma radiation as well they could potentially be used as the imaging radionuclide as well as the therapeutic radionuclide. However, the downsides are that the beta radiation will deliver a significant radiation dose as part of the treatment planning procedure, and the gamma radiation branching ratio is often quite low. Gallium-۶۷ has been in use in nuclear medicine for over ۵۰ years. However, the tremendous interest in gallium imaging in theranostics in recent times has focused on the PET radionuclide gallium-۶۸. In this article it is suggested that the longer-lived gallium-۶۷, which has desirable characteristics for imaging with the gamma camera and a suitably long half-life to match biological timescales for drug uptake and turnover, has been overlooked, in particular, for treatment planning with radionuclide therapy. Gallium-۶۷ could also allow non-PET facilities to participate in theranostic imaging prior to treatment or for monitoring response after therapy. Gallium-۶۷ could play a niche role in the future development of personalised medicine with theranostics.
کلیدواژه ها:
نویسندگان
Dale Bailey
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
Dhanusha Sabanathan
GlyTherix Ltd, Sydney, Australia
Alireza Aslani
Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
Douglas Campbell
GlyTherix Ltd, Sydney, Australia
Bradley Walsh
GlyTherix Ltd, Sydney, Australia
Nigel Lengkeek
Biosciences, Australian Nuclear Science & Technology Organisation (ANSTO), Sydney, Australia
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :